Published in final edited form as:

Biochem Soc Trans. 2016 October 15; 44(5): 1313–1319. doi:10.1042/BST20160150.

Regulation of the phosphatase PP2B by protein–protein interactions

Patrick J. Nygren^{1,2} and John D. Scott^{1,2}

¹Department of Pharmacology, University of Washington, Seattle, WA 98195, USA

²Howard Hughes Medical Institute, University of Washington, Seattle, WA 98195, USA

Abstract

Protein dephosphorylation is important for regulating cellular signaling in a variety of contexts. Protein phosphatase-2B (PP2B), or calcineurin, is a widely expressed serine/threonine phosphatase that acts on a large cross section of potential protein substrates when activated by increased levels of intracellular calcium in concert with calmodulin. PxIxIT and LxVP targeting motifs are important for maintaining specificity in response to elevated calcium. In the present study, we describe the mechanism of PP2B activation, discuss its targeting by conserved binding motifs and review recent advances in the understanding of an A-kinase anchoring protein 79/PP2B/protein kinase A complex's role in synaptic long-term depression. Finally, we discuss potential for targeting PP2B anchoring motifs for therapeutic benefit.

PP2B targeting by substrate interaction motifs and anchoring proteins

The present study focuses on how protein–protein interactions between protein phosphatase-2B (PP2B), also known as calcineurin, and substrates and anchoring proteins influence physiological processes controlled by this enzyme.

Reversible protein phosphorylation is perhaps the most well-studied post-translational modification [1]. It has been shown to be vital for almost all cellular signaling pathways, regulating signaling events in response to input from extracellular cues or from modulatory signaling cross-talk. Attachment of phosphate groups to protein substrates by kinases is reversed by the action of protein phosphatases, which are often specific for phosphotyrosine or phosphoserine/threonine residues.

PP2B is a ubiquitous serine (Ser)/threonine (Thr) phosphatase that is activated by elevated calcium levels and subsequent activation of calmodulin (CaM) [2]. The PP2B holoenzyme is a heterodimer that consists of a catalytic A subunit and a regulatory B subunit. When activated, this holoenzyme includes CaM in its calcium-bound state. Elevation of calcium and activation of CaM cause a structural rearrangement that allows CaM to bind to an α -

Correspondence: John D. Scott (scottjd@uw.edu).

Competing Interests

The Authors declare that there are no competing interests associated with the manuscript.

helix in the A subunit of PP2B and remove an autoinhibitory helix from the active site of the phosphatase (Figure 1A) [3].

Because PP2B has the capacity to promiscuously dephosphorylate most solvent-exposed Ser/Thr residues, the controlled activation and inactivation by calcium transients is important for signaling specificity [4]. Moreover, substrate specificity is controlled by a variety of protein–protein interactions with anchoring proteins and allosteric recognition sequences on PP2B substrates [5–7]. In particular, the A-kinase anchoring protein 79 (AKAP79, AKAP150 in rodents; products of the *AKAP5* gene), interacts with both PP2B and protein kinase A (PKA) [8,9]. This co-localization of a kinase and a phosphatase permits exquisite control of post-translationally mediated signaling events [10,11].

PP2B's interactions with binding partners ensure that this broad spectrum phosphatase can have specific roles in diverse physiological contexts, such as neurotransmission, cardiac signaling, immune responses, and insulin signaling. We will describe the molecular basis for interactions between PP2B and anchoring proteins/substrates, and review how these interactions control cellular signaling events.

Anchoring and substrate interactions

The catalytic subunit of PP2B resembles the catalytic subunit of protein phosphatase-1 (PP1) [5,12]. However, while PP1 holoenzymes are formed via interactions with a large variety of regulatory and targeting subunits [13], PP2B holoenzymes can be formed with different combinations of three catalytic A-subunit isoforms (α , β , and γ) and two regulatory B-subunit isoforms (type 1 and type 2) [3,14,15]. These isoforms lack both the structural and functional diversity of targeted PP1 holoenzymes; therefore, the varied roles of PP2B in biological processes are often mediated by a similarly diverse range of interacting proteins.

However, the majority of these interactions are through two distinct surfaces on PP2B. The best-characterized surface is composed of a β -sheet on the catalytic subunit. This β -sheet interacts with a conserved motif known as the PxIxIT motif. The PxIxIT motif forms a short β -strand that interacts with β -strand 14 of the catalytic subunit and extends the β -sheet (Figure 1A) [16,17].

Several interacting proteins contain the PxIxIT motif, notably the canonical PP2B substrate nuclear factor of activated T-cells (NFAT) [18] and AKAP79/150 (Table 1) [19,20]. Other proteins that contain PxIxIT motifs include the scaffolding protein regulator of calcineurin 1 (RCAN1) [21] and the TWIK-related spinal cord potassium channel (TRESK) [5]. The primary function of the PxIxIT motif is thought to be to spatially recruit PP2B to nearby substrates. Structures of PP2B in complex with a synthetic PxIxIT peptide [17], as well as a PxIxIT peptide analog derived from AKAP79 [16], have been solved by crystallography.

A more recently characterized PP2B-interacting motif is termed the LxVP motif. This motif binds near the interface of the catalytic and regulatory subunits of PP2B and forms important contacts with both subunits (Figure 1A) [6,22]. This interface is also spatially removed from the active site of the phosphatase, although it has been suggested that it serves to optimally place phosphosubstrates for efficient dephosphorylation [22]. This is supported by the

observation that LxVP motifs only bind to activated PP2B (in the presence of calcium and CaM). In addition, the LxVP-binding site overlaps with the binding site for the immunosuppressant/immunophilin complexes cyclosporin/cyclophilin and FK506/FKBP12 [22]. A recent study suggests that the main mechanism of action for these immunosuppressants is to compete for binding with the LxVP motif present in NFAT. This conserved LxVP motif seems to have a looser consensus sequence than the PxIxIT, and the key requirements for binding have not yet been fully defined [5,22].

The LxVP motif was originally identified in a region of the RII α regulatory subunit of PKA that was used as a substrate peptide for the phosphatase [23]. However, the LxVP sequence was not recognized as a consensus motif at that time. Subsequent analyses revealed that NFAT contains an LxVP motif, as do other PP2B substrates. In addition, a peptide derived from a viral protein that contains both an LxVP motif and a PxIxIT motif was co-crystallized with PP2B, and the resulting structure has shed light on the binding site of the LxVP motif (Table 1) [22].

Proteins that contain LxVP motifs have been shown to use them for various purposes. NFAT family members use the LxVP motif to stimulate dephosphorylation of phosphosites located between the LxVP motif and the PxIxIT motif [5]. The scaffold protein KSR2 appears to only have an LxVP motif and lacks a PxIxIT, and this promotes dephosphorylation of upstream distal Ser and Thr residues [24]. Because of the flexibility inherent in the LxVP motif, it is likely that most proteins contain regions of disorder surrounding the LxVP motif that act analogously to the disorder in RII, allowing a range of nearby phosphosites to occupy a constrained yet flexible conformational space so that multiple sites can be dephosphorylated by a single-anchored PP2B molecule [22].

As more LxVP motifs are identified in other proteins, undoubtedly the function and consensus of this sequence will be more well understood. The combination of multiple binding motifs for a single phosphatase allows fine-tuning of binding affinities under different enzymatic states, while also possibly influencing substrate selectivity. The potential for the LxVP motif to fine-tune the activity and specificity of PP2B may be important for understanding how anchored PP2B acts in regulating synaptic transmission.

Postsynaptic signaling

Synaptic plasticity — the ability of synapses to undergo changes in the strength of their response to neurotransmitter release — is believed to underlie aspects of contextual learning and memory [25,26]. Many of these changes are mediated by *N*-methyl-D-aspartate (NMDA) and α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptors on the postsynaptic neuron, which are modulated by phosphorylation events. These covalent modifications promote changes in the number of receptors at the synapse, as well as changes to receptor ion permeability [27]. AMPA receptors are tetrameric channels that are composed of some combination of four different subunit isoforms — GluA1–4. Homomeric GluA1/1 receptors are calcium permeable, while heteromeric receptors that contain GluA2 are considered to be calcium impermeable [28].

PP2B has been suggested to be particularly important for modulating the phosphorylation state of Ser845 of the GluA1 subunit of the AMPA receptor in the hippocampal region of the brain [29–31]. Phosphorylation of Ser845 increases ion permeability and also results in increased trafficking to the postsynaptic density [29]. PP2B has long been implicated in dephosphorylation of this site in response to high-frequency stimulation and is targeted to AMPA receptors by a protein complex that involves AKAP79 and, the membrane-associated guanylate kinase protein, synapse-associated protein 97 (SAP97) [29,32]. SAP97 is a scaffolding protein that interacts with the GluA1 subunit of the AMPA receptor and with AKAP79 to form a macromolecular complex that serves as an important signaling node in the postsynaptic density [33,34].

While the dephosphorylation of Ser845 has been known to be important for a form of synaptic plasticity called NMDA receptor-dependent long-term depression (LTD), the exact molecular mechanisms have not been clear [35,36]. Early work implicated a PP2B/PP1 cascade in regulating this type of LTD; however, previous studies suggest that PP2B directly dephosphorylates Ser845 [37–40]. Recent work highlights the importance of the AKAP79/150 complex containing both PKA and PP2B in inducing LTD in the CA1 region of the hippocampus [41–43]. It is also important to note that a role of AKAP79/150 interactions with GABA receptors at inhibitory synapses has also been proposed. Therefore, AKAP79/150 may be a more general synaptic anchoring protein that co-ordinates the differential localization of PP2B and a variety of other kinases to various synaptic sites [44].

After initial studies with AKAP150 knockout mice [36], several knock-in mouse models were generated which express forms of the anchoring protein that lack binding sites for PKA (PKA) [35], protein kinase C (PKC) [45], or PP2B (PIX) [30]. These mouse models have been used to study a variety of physiological arenas, such as vascular smooth muscle [45,46], cardiac function [47,48], and glucose homeostasis [49]. Recently, the PIX and PKA mouse lines have been used to show that in the postsynaptic density, AKAP79/150-anchored PKA is necessary to phosphorylate homomeric GluA1 AMPA receptors at Ser845 and recruit them in rapid response to calcium influx through NMDA receptors. These homomeric calcium permeable GluA1 receptors are recruited to the synapse and augment the later calcium response to glutamate in order to efficiently activate AKAP79/150-anchored PP2B [42]. This PP2B activation promotes GluA1 dephosphorylation to remove both the homomeric GluA1 AMPA receptors and the heteromeric ionotropic glutamate receptors 1/2, resulting in an overall decrease in synaptic strength [42]. This activated PP2B has also been shown to be important in spine shrinkage and trafficking of AKAP79/150 and MAGUK protein complexes away from the postsynaptic density [19,33,50,51].

Another long-standing puzzle in neuronal signaling has been the relative activity of the Ca^{2+} /CaM-dependent protein kinase II (CaMKII) and PP2B in response to postsynaptic influxes of calcium. Both enzymes are activated by calcium/CaM and have many overlapping substrates, such as the GluA1 subunit of the AMPA receptor, the NMDA receptor, and other postsynaptic targets [50,52]. How these enzymes are differentially regulated may be explained not only by their differential sensitivity to calcium, but also by their localization within the postsynaptic density by anchoring and substrate interactions. In addition, previous studies have implicated neuronal pools of AKAP79-anchored PP2B in

dephosphorylation of NFAT in response to calcium entry via the L-type calcium channel [16,19].

As more is learned about the functional effects of PP2B anchoring, light will be shed on these questions as well as on the role of PP2B in the other diverse physiological events it helps control.

Conclusion: targeting PP2B for therapeutics

PP2B is an important therapeutic target for cyclosporin and FK506, immunosuppressants used clinically for organ transplant patients as well as to treat psoriasis and rheumatoid arthritis [53–55]. However, its role in synaptic plasticity, as well as in other processes such as insulin signaling [49], and cardiac function [56–58] make PP2B an attractive potential target for other conditions. In order to effectively target specific pathways, PP2B's interactions with anchoring proteins, such as AKAP79 or specific phosphosubstrates, need to be disrupted. This requires a detailed understanding of what the structural basis for these interactions is, as well as the relative functions of the PxIxIT and LxVP-binding motifs.

Several small molecules that disrupt PP2B interactions have already been developed, including the INCA compounds [59] and the VIVIT peptide [17,60], both of which disrupt interactions with the PxIxIT motif. The fact that binding sites for the LxVP motif and the immunophilin complexes overlap suggests that the targeted disruption of PP2B's interaction with the LxVP motif is a promising avenue for specific therapeutic treatment [22]. Because PP2B has a wide range of potential targets, targeting the catalytic site of PP2B is likely to have a plethora of undesirable effects, whereas targeting interaction motifs will provide the best specificity. Only a more thorough understanding of the function and molecular details of these interaction motifs will allow such an approach to be successful.

Acknowledgments

We thank members of the Scott lab for fruitful discussions that informed this review, and apologize to deserving studies which were not able to be cited due to space restrictions.

Funding

This work was supported by National Institutes of Health Grants [DK105542] and [DK054441] (to J.D.S).

Abbreviations

AKAP	A-kinase anchoring protein
AMPA	α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
CaM	calmodulin
CaMKII	Ca^{2+} /CaM-dependent protein kinase II
LTD	long-term depression
NFAT	nuclear factor of activated T-cells

NMDA	<i>N</i> -methyl-D-aspartate
PKA	protein kinase A
PP1	protein phosphatase-1
PP2B	protein phosphatase-2B
RCAN1	regulator of calcineurin 1
SAP97	synapse-associated protein 97
Ser	serine
Thr	threonine
TRESK	TWIK-related spinal cord potassium channel

References

1. Pawson T, Scott JD. Protein phosphorylation in signaling – 50 years and counting. *Trends Biochem Sci.* 2005; 30:286–290. DOI: 10.1016/j.tibs.2005.04.013 [PubMed: 15950870]
2. Stewart AA, Ingebritsen TS, Manalan A, Klee CB, Cohen P. Discovery of a Ca^{2+} - and calmodulin-dependent protein phosphatase. *FEBS Lett.* 1982; 137:80–84. DOI: 10.1016/0014-5793(82)80319-0 [PubMed: 6279434]
3. Li H, Rao A, Hogan PG. Interaction of calcineurin with substrates and targeting proteins. *Trends Cell Biol.* 2011; 21:91–103. DOI: 10.1016/j.tcb.2010.09.011 [PubMed: 21115349]
4. Mehta S, Aye-Han NN, Ganesan A, Oldach L, Gorshkov K, Zhang J. Calmodulin-controlled spatial decoding of oscillatory Ca^{2+} signals by calcineurin. *eLife.* 2014; 3:e03765.doi: 10.7554/eLife.03765 [PubMed: 25056880]
5. Roy J, Cyert MS. Cracking the phosphatase code: docking interactions determine substrate specificity. *Sci Signal.* 2009; 2:re9.doi: 10.1126/scisignal.2100re9 [PubMed: 19996458]
6. Rodríguez A, Roy J, Martínez-Martínez S, López-Maderuelo MD, Niño-Moreno P, Ortí L, et al. A conserved docking surface on calcineurin mediates interaction with substrates and immunosuppressants. *Mol Cell.* 2009; 33:616–626. DOI: 10.1016/j.molcel.2009.01.030 [PubMed: 19285944]
7. Roy J, Li H, Hogan PG, Cyert MS. A conserved docking site modulates substrate affinity for calcineurin, signaling output, and in vivo function. *Mol Cell.* 2007; 25:889–901. DOI: 10.1016/j.molcel.2007.02.014 [PubMed: 17386265]
8. Coghlan VM, Perrino BA, Howard M, Langeberg LK, Hicks JB, Gallatin WM, et al. Association of protein kinase A and protein phosphatase 2B with a common anchoring protein. *Science.* 1995; 267:108–111. DOI: 10.1126/science.7528941 [PubMed: 7528941]
9. Carr DW, Hausken ZE, Fraser ID, Stofko-Hahn RE, Scott JD. Association of the type II cAMP-dependent protein kinase with a human thyroid RII-anchoring protein. Cloning and characterization of the RII-binding domain *J Biol Chem.* 1992; 267:13376–13382. [PubMed: 1618839]
10. Tasken K, Aandahl EM. Localized effects of cAMP mediated by distinct routes of protein kinase A. *Physiol. Rev.* 2004; 84:137–167. DOI: 10.1152/physrev.00021.2003
11. Langeberg LK, Scott JD. Signalling scaffolds and local organization of cellular behaviour. *Nat Rev Mol Cell Biol.* 2015; 16:232–244. DOI: 10.1038/nrm3966 [PubMed: 25785716]
12. Choy MS, Hieke M, Kumar GS, Lewis GR, Gonzalez-DeWhitt KR, Kessler RP, et al. Understanding the antagonism of retinoblastoma protein dephosphorylation by PNUTS provides insights into the PP1 regulatory code. *Proc Natl Acad Sci USA.* 2014; 111:4097–4102. DOI: 10.1073/pnas.1317395111 [PubMed: 24591642]
13. Bollen M. Combinatorial control of protein phosphatase-1. *Trends Biochem Sci.* 2001; 26:426–431. DOI: 10.1016/S0968-0004(01)01836-9 [PubMed: 11440854]

14. Guerini D, Klee CB. Structural diversity of calcineurin, a Ca^{2+} and calmodulin-stimulated protein phosphatase. *Adv Protein Phosphatases*. 1991; 6:391–410.
15. Kuno T, Takida T, Hirai M, Ito A, Mukai H, Tanaka C. Evidence for a second isoform of the catalytic subunit of calmodulin-dependent protein phosphatase (calcineurin A). *Biochem Biophys Res Commun*. 1989; 165:1352–1358. DOI: 10.1016/0006-291X(89)92752-6 [PubMed: 2558657]
16. Li H, Pink MD, Murphy JG, Stein A, Dell'acqua ML, Hogan PG. Balanced interactions of calcineurin with AKAP79 regulate Ca^{2+} -calcineurin-NFAT signaling. *Nat Struct Mol Biol*. 2012; 19:337–345. DOI: 10.1038/nsmb.2238 [PubMed: 22343722]
17. Li H, Zhang L, Rao A, Harrison SC, Hogan PG. Structure of calcineurin in complex with PVIVIT peptide: portrait of a low-affinity signalling interaction. *J Mol Biol*. 2007; 369:1296–1306. DOI: 10.1016/j.jmb.2007.04.032 [PubMed: 17498738]
18. Park S, Uesugi M, Verdine GL. A second calcineurin binding site on the NFAT regulatory domain. *Proc Natl Acad Sci USA*. 2000; 97:7130–7135. DOI: 10.1073/pnas.97.13.7130 [PubMed: 10860980]
19. Oliveria SF, Dell'Acqua ML, Sather WA. AKAP79/150 anchoring of calcineurin controls neuronal L-type Ca^{2+} channel activity and nuclear signaling. *Neuron*. 2007; 55:261–275. DOI: 10.1016/j.neuron.2007.06.032 [PubMed: 17640527]
20. Dell'Acqua ML, Dodge KL, Tavalin SJ, Scott JD. Mapping the protein phosphatase-2B anchoring site on AKAP79 Binding and inhibition of phosphatase activity are mediated by residues 315–360. *J Biol Chem*. 2002; 277:48796–48802. DOI: 10.1074/jbc.M207833200 [PubMed: 12354762]
21. Mehta S, Li H, Hogan PG, Cunningham KW. Domain architecture of the regulators of calcineurin (RCANs) and identification of a divergent RCAN in yeast. *Mol Cell Biol*. 2009; 29:2777–2793. DOI: 10.1128/MCB.01197-08 [PubMed: 19273587]
22. Grigoriu S, Bond R, Cossio P, Chen JA, Ly N, Hummer G, et al. The molecular mechanism of substrate engagement and immunosuppressant inhibition of calcineurin. *PLoS Biol*. 2013; 11:e1001492. doi: 10.1371/journal.pbio.1001492 [PubMed: 23468591]
23. Blumenthal DK, Takio K, Hansen RS, Krebs EG. Dephosphorylation of cAMP-dependent protein kinase regulatory subunit (type II) by calmodulin-dependent protein phosphatase. *J Biol Chem*. 1986; 261:8140–8145. [PubMed: 3013843]
24. Dougherty MK, Ritt DA, Zhou M, Specht SI, Monson DM, Veenstra TD, et al. KSR2 is a calcineurin substrate that promotes ERK cascade activation in response to calcium signals. *Mol Cell*. 2009; 34:652–662. DOI: 10.1016/j.molcel.2009.06.001 [PubMed: 19560418]
25. Sheng M, Kim MJ. Postsynaptic signaling and plasticity mechanisms. *Science*. 2002; 298:776–780. DOI: 10.1126/science.1075333 [PubMed: 12399578]
26. Huganir RL, Nicoll RA. AMPARs and synaptic plasticity: the last 25 years. *Neuron*. 2013; 80:704–717. DOI: 10.1016/j.neuron.2013.10.025 [PubMed: 24183021]
27. Malinow R, Malenka RC. AMPA receptor trafficking and synaptic plasticity. *Annu Rev Neurosci*. 2002; 25:103–126. DOI: 10.1146/annurev.neuro.25.112701.142758 [PubMed: 12052905]
28. Lu W, Shi Y, Jackson AC, Bjorgan K, During MJ, Sprengel R, et al. Subunit composition of synaptic AMPA receptors revealed by a single-cell genetic approach. *Neuron*. 2009; 62:254–268. DOI: 10.1016/j.neuron.2009.02.027 [PubMed: 19409270]
29. Tavalin SJ, Colledge M, Hell JW, Langeberg LK, Huganir RL, Scott JD. Regulation of GluR1 by the A-kinase anchoring protein 79 (AKAP79) signaling complex shares properties with long-term depression. *J Neurosci*. 2002; 22:3044–3051. [PubMed: 11943807]
30. Sanderson JL, Gorski JA, Gibson ES, Lam P, Freund RK, Chick WS, et al. AKAP150-anchored calcineurin regulates synaptic plasticity by limiting synaptic incorporation of Ca^{2+} -permeable AMPA receptors. *J Neurosci*. 2012; 32:15036–15052. DOI: 10.1523/JNEUROSCI.3326-12.2012 [PubMed: 23100425]
31. Joiner, M-IA; Lisé, MF.; Yuen, EY.; Kam, AYT.; Zhang, M.; Hall, DD., et al. Assembly of a β_2 -adrenergic receptor—GluR1 signalling complex for localized cAMP signalling. *EMBO J*. 2010; 29:482–495. DOI: 10.1038/emboj.2009.344 [PubMed: 19942860]
32. Jurado S, Biou V, Malenka RC. A calcineurin/AKAP complex is required for NMDA receptor-dependent long-term depression. *Nat Neurosci*. 2010; 13:1053–1055. DOI: 10.1038/nn.2613 [PubMed: 20694001]

33. Robertson HR, Gibson ES, Benke TA, Dell'Acqua ML. Regulation of postsynaptic structure and function by an A-kinase anchoring protein-membrane-associated guanylate kinase scaffolding complex. *J Neurosci*. 2009; 29:7929–7943. DOI: 10.1523/JNEUROSCI.6093-08.2009 [PubMed: 19535604]
34. Colledge M, Dean RA, Scott GK, Langeberg LK, Haganir RL, Scott JD. Targeting of PKA to glutamate receptors through a MAGUK-AKAP complex. *Neuron*. 2000; 27:107–119. DOI: 10.1016/S0896-6273(00)00013-1 [PubMed: 10939335]
35. Weisenhaus M, Allen ML, Yang L, Lu Y, Nichols CB, Su T, et al. Mutations in AKAP5 disrupt dendritic signaling complexes and lead to electrophysiological and behavioral phenotypes in mice. *PLoS ONE*. 2010; 5:e10325.doi: 10.1371/journal.pone.0010325 [PubMed: 20428246]
36. Tunquist BJ, Hoshi N, Guire ES, Zhang F, Mullendorff K, Langeberg LK, et al. Loss of AKAP150 perturbs distinct neuronal processes in mice. *Proc Natl Acad Sci USA*. 2008; 105:12557–12562. DOI: 10.1073/pnas.0805922105 [PubMed: 18711127]
37. Morishita W, Connor JH, Xia H, Quinlan EM, Shenolikar S, Malenka RC. Regulation of synaptic strength by protein phosphatase 1. *Neuron*. 2001; 32:1133–1148. DOI: 10.1016/S0896-6273(01)00554-2 [PubMed: 11754843]
38. Mulkey RM, Endo S, Shenolikar S, Malenka RC. Involvement of a calcineurin/inhibitor-1 phosphatase cascade in hippocampal long-term depression. *Nature*. 1994; 369:486–488. DOI: 10.1038/369486a0 [PubMed: 7515479]
39. Snyder GL, Galdi S, Fienberg AA, Allen P, Nairn AC, Greengard P. Regulation of AMPA receptor dephosphorylation by glutamate receptor agonists. *Neuropharmacology*. 2003; 45:703–713. DOI: 10.1016/S0028-3908(03)00319-8 [PubMed: 14529709]
40. Beattie EC, Carroll RC, Yu X, Morishita W, Yasuda H, von Zastrow M, et al. Regulation of AMPA receptor endocytosis by a signaling mechanism shared with LTD. *Nat Neurosci*. 2000; 3:1291–1300. DOI: 10.1038/81823 [PubMed: 11100150]
41. Snyder EM, Colledge M, Crozier RA, Chen WS, Scott JD, Bear MF. Role for A kinase-anchoring proteins (AKAPS) in glutamate receptor trafficking and long term synaptic depression. *J Biol Chem*. 2005; 280:16962–16968. DOI: 10.1074/jbc.M409693200 [PubMed: 15718245]
42. Sanderson JL, Gorski JA, Dell'Acqua ML. NMDA receptor-dependent LTD requires transient synaptic incorporation of Ca^{2+} -permeable AMPARs mediated by AKAP150-anchored PKA and calcineurin. *Neuron*. 2016; 89:1000–1015. DOI: 10.1016/j.neuron.2016.01.043 [PubMed: 26938443]
43. Hell JW. How Ca^{2+} -permeable AMPA receptors, the kinase PKA, and the phosphatase PP2B are intertwined in synaptic LTP and LTD. *Sci Signal*. 2016; 9:pe2.doi: 10.1126/scisignal.aaf7067 [PubMed: 27117250]
44. Brandon NJ, Jovanovic JN, Colledge M, Kittler JT, Brandon JM, Scott JD, et al. A-kinase anchoring protein 79/150 facilitates the phosphorylation of GABA(A) receptors by cAMP-dependent protein kinase via selective interaction with receptor β subunits. *Mol Cell Neurosci*. 2003; 22:87–97. DOI: 10.1016/S1044-7431(02)00017-9 [PubMed: 12595241]
45. Mercado J, Baylie R, Navedo MF, Yuan C, Scott JD, Nelson MT, et al. Local control of TRPV4 channels by AKAP150-targeted PKC in arterial smooth muscle. *J Gen Physiol*. 2014; 143:559–575. DOI: 10.1085/jgp.201311050 [PubMed: 24778429]
46. Nystoriak MA, Nieves-Cintrón M, Nygren PJ, Hinke SA, Nichols CB, Chen CY, et al. AKAP150 contributes to enhanced vascular tone by facilitating large-conductance Ca^{2+} -activated K^{+} channel remodeling in hyperglycemia and diabetes mellitus. *Circ Res*. 2014; 114:607–615. DOI: 10.1161/CIRCRESAHA.114.302168 [PubMed: 24323672]
47. Cheng EP, Yuan C, Navedo MF, Dixon RE, Nieves-Cintrón M, Scott JD, et al. Restoration of normal L-type Ca^{2+} channel function during Timothy syndrome by ablation of an anchoring protein. *Circ Res*. 2011; 109:255–261. DOI: 10.1161/CIRCRESAHA.111.248252 [PubMed: 21700933]
48. Nichols CB, Rossow CF, Navedo MF, Westenbroek RE, Catterall WA, Santana LF, et al. Sympathetic stimulation of adult cardiomyocytes requires association of AKAP5 with a subpopulation of L-type calcium channels. *Circ Res*. 2010; 107:747–756. DOI: 10.1161/CIRCRESAHA.109.216127 [PubMed: 20671242]

49. Hinke SA, Navedo MF, Ulman A, Whiting JL, Nygren PJ, Tian G, et al. Anchored phosphatases modulate glucose homeostasis. *EMBO J.* 2012; 31:3991–4004. DOI: 10.1038/emboj.2012.244 [PubMed: 22940692]
50. Sanderson JL, Dell'Acqua ML. AKAP signaling complexes in regulation of excitatory synaptic plasticity. *Neuroscientist.* 2011; 17:321–336. DOI: 10.1177/1073858410384740 [PubMed: 21498812]
51. Oliveria SF, Gomez LL, Dell'Acqua ML. Imaging kinase–AKAP79–phosphatase scaffold complexes at the plasma membrane in living cells using FRET microscopy. *J Cell Biol.* 2003; 160:101–112. DOI: 10.1083/jcb.200209127 [PubMed: 12507994]
52. Swope SL, Moss SJ, Raymond LA, Haganir RL. Regulation of ligand-gated ion channels by protein phosphorylation. *Adv Second Messenger Phosphoprotein Res.* 1999; 33:49–78. DOI: 10.1016/S1040-7952(99)80005-6 [PubMed: 10218114]
53. McCaffrey PG, Luo C, Kerppola TK, Jain J, Badalian TM, Ho AM, et al. Isolation of the cyclosporin-sensitive T cell transcription factor NFATp. *Science.* 1993; 262:750–754. DOI: 10.1126/science.8235597 [PubMed: 8235597]
54. Haddy A, Swanson SKH, Born TL, Rusnak F. Inhibition of calcineurin by cyclosporin A–cyclophilin requires calcineurin B. *FEBS Lett.* 1992; 314:37–40. DOI: 10.1016/0014-5793(92)81456-V [PubMed: 1333415]
55. Liu J, Farmer JDJ, Lane WL, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin–cyclosporin A and FKBP–FK506 complexes. *Cell.* 1991; 66:807–815. DOI: 10.1016/0092-8674(91)90124-H [PubMed: 1715244]
56. Li J, Negro A, Lopez J, Bauman AL, Henson E, Dodge-Kafka K, et al. The mAKAP β scaffold regulates cardiac myocyte hypertrophy via recruitment of activated calcineurin. *J Mol Cell Cardiol.* 2010; 48:387–394. DOI: 10.1016/j.jmcc.2009.10.023 [PubMed: 19883655]
57. Santana LF, Chase EG, Votaw VS, Nelson MT, Greven R. Functional coupling of calcineurin and protein kinase A in mouse ventricular myocytes. *J Physiol.* 2002; 544:57–69. DOI: 10.1113/jphysiol.2002.020552 [PubMed: 12356880]
58. De Windt LJ, Lim HW, Bueno OF, Liang Q, Delling U, Braz JC, et al. Targeted inhibition of calcineurin attenuates cardiac hypertrophy *in vivo*. *Proc Natl Acad Sci USA.* 2001; 98:3322–3327. DOI: 10.1073/pnas.031371998 [PubMed: 11248077]
59. Kang S, Li H, Rao A, Hogan PG. Inhibition of the calcineurin–NFAT interaction by small organic molecules reflects binding at an allosteric site. *J Biol Chem.* 2005; 280:37698–37706. DOI: 10.1074/jbc.M502247200 [PubMed: 16148011]
60. Yu H, van Berkel TJC, Biessen EAL. Therapeutic potential of VIVIT, a selective peptide inhibitor of nuclear factor of activated T cells, in cardiovascular disorders. *Cardiovasc Drug Rev.* 2007; 25:175–187. DOI: 10.1111/j.1527-3466.2007.00011.x [PubMed: 17614939]
61. Lai MM, Burnett PE, Wolosker H, Blackshaw S, Snyder SH. Cain, a novel physiologic protein inhibitor of calcineurin. *J Biol Chem.* 1998; 273:18325–18331. DOI: 10.1074/jbc.273.29.18325 [PubMed: 9660798]
62. Wesselborg S, Fruman DA, Sagoo JK, Bierer BE, Burakoff SJ. Identification of a physical interaction between calcineurin and nuclear factor of activated T cells (NFATp). *J Biol Chem.* 1996; 271:1274–1277. DOI: 10.1074/jbc.271.3.1274 [PubMed: 8576111]
63. Czirájk G, Enyedi P. The LQLP calcineurin docking site is a major determinant of the calcium-dependent activation of human TRESK background K⁺ channel. *J Biol Chem.* 2014; 289:29506–29518. DOI: 10.1074/jbc.M114.577684 [PubMed: 25202008]
64. Czirájk G, Enyedi P. Targeting of calcineurin to an NFAT-like docking site is required for the calcium-dependent activation of the background K⁺ channel, TRESK. *J Biol Chem.* 2006; 281:14677–14682. DOI: 10.1074/jbc.M602495200 [PubMed: 16569637]
65. Slupe AM, Merrill RA, Flippo KH, Lobas MA, Houtman JCD, Strack S. A calcineurin docking motif (LXVP) in dynamin-related protein 1 contributes to mitochondrial fragmentation and ischemic neuronal injury. *J Biol Chem.* 2013; 288:12353–12365. DOI: 10.1074/jbc.M113.459677 [PubMed: 23486469]

66. Kolozsvari B, Bako E, Becsi B, Kiss A, Czikora A, Toth A, et al. Calcineurin regulates endothelial barrier function by interaction with and dephosphorylation of myosin phosphatase. *Cardiovasc Res.* 2012; 96:494–503. DOI: 10.1093/cvr/cvs255 [PubMed: 22869619]
67. Bodmer D, Ascaño M, Kuruvilla R. Isoform-specific dephosphorylation of dynamin1 by calcineurin couples neurotrophin receptor endocytosis to axonal growth. *Neuron.* 2011; 70:1085–1099. DOI: 10.1016/j.neuron.2011.04.025 [PubMed: 21689596]

Figure 1.

(A) Schematic of PP2B (gray) activation by CaM (green) and calcium. Structural rearrangement of the autoinhibitory helix (red) allows catalytic activity. PxlIT (blue) and LxVP (orange) binding surfaces are indicated, as well as the approximate location of the active site (red circle). (B) AKAP79/SAP97-mediated complex of GluA1-containing AMPA receptors, PP2B and PKA. Upon elevation of calcium, PKA and PP2B work in a distinct manner to promote long-term depression through regulation of AMPA receptors.

Table 1

PP2B-binding motifs in anchoring proteins and substrates

PP2B-binding partner	Demonstrated phosphosubstrate	PxIxIT motif identified	LxVP motif identified	References
Cain/Cabin1	Yes	Yes	No	[61]
NFAT	Yes	Yes	Yes	[62]
RCAN1	Yes	Yes	Yes	[21]
AKAP79	Yes	Yes	No	[19,20]
KSR2	Yes	No	Yes	[24]
TRESK	Yes	Yes	Yes	[63,64]
PKA-RII α	Yes	No	Yes	[23]
DRP1	Yes	No	Yes	[65]
A238L	No	Yes	Yes	[22]
Myosin phosphatase	Yes	Yes	No	[66]
Dynamin 1	Yes	Yes	No	[67]